Introduction:
Leading pharmaceutical company has received a Letter of Award from UNICEF to supply 115 million doses of bivalent oral polio vaccine (bOPV) in 2025, valued at approximately US$ 14.95 million (₹127 crore), supporting global polio eradication efforts.
Also Read: Stocks to Consider for This New Year 2025
Share price movement of Panacea Biotec:
On December 26, 2024, Panacea Biotec Ltd. opened at ₹456.25, up 4.99% from its previous close of ₹434.55. The stock reached a high of ₹456.25 (4.99%) and a low of ₹454.00. By 10:24 AM, it traded at ₹456.25, with a market cap of ₹2,794.57 crore.
Panacea Biotec Secures UNICEF Order for Polio Vaccine Supply:
Panacea Biotec Limited announced receiving a Letter of Award from UNICEF for supplying 115 million doses of its bivalent oral polio vaccine (bOPV) in 2025, valued at approximately US$ 14.95 million (₹127 crore).
The company’s successful bid highlights its strong position in the global vaccine market, as it prepares to deliver bOPV to UNICEF under the terms of the contract. This significant order will contribute to global polio eradication efforts.
The contract, covering the supply for CY2025, reflects Panacea Biotec’s commitment to supporting public health initiatives. The company provided all required details in accordance with SEBI regulations.
Recent news on Panacea Biotec:
As of October 04, 2024, Panacea Biotec surged following news of its dengue vaccine development. The vaccine, in phase three trials across 19 Indian sites, is progressing well, with plans to seek DCGI approval after trial completion.
Stock performance of Panacea Biotec for Period of 1 week, 6 months and 1 year:
Panacea Biotec Ltd. saw a 5.49% decline over the past week, reflecting short-term volatility. However, the company experienced impressive growth with a 223% return over the last six months and a 156% return over the past year.
Also Read: Semiconductor stock with strong future growth guidance to keep on your radar
Shareholding pattern of Panacea Biotec:
All values in % | Sep 2024 | Jun 2024 | Mar 2024 |
Promoter | 72.90% | 73.50% | 73.60% |
FII | 0.40% | 0.30% | 0.30% |
DII | 1.20% | 1.10% | 0.80% |
Public | 25.60% | 25.20% | 25.30% |
About Panacea Biotec:
Panacea Biotec (NSE: PANACEABIO), established in 1984, is a leading research-based health management company in India. Specializing in vaccines and pharmaceutical formulations, it has advanced manufacturing facilities and collaborates with global research organizations.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.